Navigation Links
ReBuilder Medical Technologies, Inc. Announces Record Sales Month
Date:11/26/2007

MRSA fears increasing public awareness of Molluscum Contagiosum

CHARLES TOWN, W.V., Nov 26 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of treatment for diabetic peripheral neuropathy and Molluscum Contagiosum today announced record breaking sales for the month of October 2007; increase is 12% above previous record which was set in September 2007.

"As public awareness of the dangers related to MRSA infections climb, treating Molluscum Contagiosum quickly and noninvasively has become imperative," says David Phillips, Ph.D. CEO. "Our record sales reflect our response to the needs of our customers by providing safe, effective alternatives to the burning, freezing, and cutting methods used by physicians that can create an increased risk for opportunistic infections like MRSA."

"We are seeing sales growth across all of our product lines. Our continuing innovation is placing us ahead of the curve. We will be releasing more news about our company's plans for expansion this week," says Dr. Phillips.

For more information visit: http://www.rebuildermedical.com and http://www.molluscum.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.


'/>"/>
SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
2. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
3. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
4. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
5. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
6. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
7. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
8. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
9. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
10. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
11. MSU engineering team designs innovative medical device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Trials I ... and tribulations as he emotionally pens his aspirations and goals to better one’s life ... published author, Jimmy Green, while searching in all the wrong places, found a love ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the inspirational solutions ... God. “Psalms of Humidity” is the creation of published author, David Waldrop, an imperfect ... are the very same things that have shaped him into the man that he ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of fundraising ... than $15,000 in just a couple of weeks for those affected by Hurricane ... instructor seminars, organizers expect to double those initial funds with the “Submit Harvey” ...
(Date:9/19/2017)... BETHESDA, MD (PRWEB) , ... September 19, 2017 ... ... of Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa ... of USAID’s Innovation to Action Award. , The Innovation to Action Award, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
Breaking Medicine Technology: